Clinical team alignment top priority for payers February 20, 2017 By Marc O'Connor Investment in resources that support clinicians and patients closer to the point of care may be the cure for what ails managed care executives. Payers to pharma: Here’s what we’re missing in hep C drugs February 17, 2017 By Tracey Walker A Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment. Managing glaucoma with surgical procedures (plural) February 15, 2017 By Robert J. Noecker MD The advent of low-risk surgical options is moving glaucoma from a pharmaceutically managed disease to one controlled via a series of surgical procedures. The outcome appears to be highly beneficial for patients, says Robert J. Noecker, MD. Value-based care takes over J.P. Morgan Healthcare Conference 2017 January 23, 2017 By Marc O'Connor Is the drive to value-based care really accelerating? What can be done amidst all of the uncertainty? Expert shares insights from the J.P. Morgan 35th Annual Healthcare Conference. Tracking treatment adherence in newly diagnosed open-angle glaucoma January 01, 2017 By Lynda Charters An analysis of U.S. claims data reveals a substantial proportion of patients (17%) remained untreated 4 years after their initial diagnosis of open-angle glaucoma. Top 10 challenges facing physicians in 2017 For the fourth consecutive year, Medical Economics reveals its list of obstacles physicians will face in the coming year and, more importantly, how to overcome them. Drug therapies, delivery systems advance for glaucoma care December 01, 2016 By Laird Harrison Pharmacologic products and devices in development continue to gain momentum in the glaucoma treatment armamentarium. Three data-driven practices that boost adherence November 17, 2016 By Neil Smiley Here’s a three-pronged approach to improve adherence program efficiency that leverages predictive data analytics, hospital on-site pharmacies and post discharge follow-up evaluation to achieve real, measurable results. Better outcomes for CF patients in monitoring program November 11, 2016 By Tracey Walker Study examines the effectiveness of the Walgreens Connected Care CF program compared to a matched sample of control patients. Three ways to rein in drug costs regardless of who becomes president October 13, 2016 By Marc O'Connor It’s time for stakeholders to cooperate in order to limit the wasted spending on prescription medications and chart a path to collectively improving value derivation.